Pliant Therapeutics (PLRX) shares were down almost 50% Monday after the company said it has ended its Beacon-IPF phase 2b trial of bexotegrast in idiopathic pulmonary fibrosis after an independent review found an imbalance in IPF-related adverse events between treatment and placebo groups.
Despite this safety concern, early data showed efficacy on forced vital capacity, the company said.
The study is the first late-stage IPF trial halted due to safety reasons while also demonstrating "strong" efficacy signals, it added.
The percentage of IPF-related adverse events in the active groups was around 10%, similar to the phase 2a Integris-IPF trial; however, the placebo group in Beacon-IPF showed a lower adverse event rate, driving the observed imbalance, according to the company.
Pliant Therapeutics said it will review the full dataset to better understand the benefit-risk profile and may plan new studies with lower doses for pulmonary fibrosis or other diseases, such as liver conditions.
Price: 1.75, Change: -1.69, Percent Change: -49.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。